CJC-1295 DAC is a synthetic, long-acting analogue of growth hormone-releasing hormone, or GHRH, designed for research involving growth-hormone signaling, IGF-1 pathways, metabolic regulation, recovery models, and body-composition-related biomarkers. The “DAC” refers to Drug Affinity Complex, a modification that extends the peptide’s activity compared with shorter-acting GHRH analogues.
In human clinical research, CJC-1295 has been studied as a long-acting GHRH analogue for its effects on growth hormone and IGF-1 secretion.
Potential Human Benefits Being Investigated
- Growth-hormone signaling research
- IGF-1 pathway research
- Lean-mass and body-composition biomarkers
- Recovery and tissue-repair pathway research
- Muscle-protein synthesis pathways
- Exercise-recovery research
- Fat-metabolism and lipolysis-related research
- Sleep-quality and slow-wave sleep research
- Cellular-repair and regeneration pathways
- Bone-density and connective-tissue research
- Collagen-turnover research
- Metabolic-health marker research
- Age-related hormone-signaling research
- Energy, vitality, and wellness-marker research
- Endocrine-function research
